Accumulation of Iron Oxide-Based Contrast Agents in Rabbit Atherosclerotic Plaques in Relation to Plaque Age and Vulnerability Features
Alexander Sekita,Harald Unterweger,Sonja Berg,Sabine Ohlmeyer,Tobias Bäuerle,Kang Zheng,Bram Coolen,Aart Nederveen,Claudia Cabella,Silvia Rossi,Erik Stroes,Christoph Alexiou,Stefan Lyer,Iwona Cicha
DOI: https://doi.org/10.2147/ijn.s430693
IF: 7.033
2024-02-20
International Journal of Nanomedicine
Abstract:Alexander Sekita, 1 Harald Unterweger, 1 Sonja Berg, 1 Sabine Ohlmeyer, 2 Tobias Bäuerle, 3 Kang H Zheng, 4 Bram F Coolen, 5 Aart J Nederveen, 6 Claudia Cabella, 7 Silvia Rossi, 7 Erik SG Stroes, 4 Christoph Alexiou, 1 Stefan Lyer, 1, &ast Iwona Cicha 1, &ast 1 ENT-Department, Section of Experimental Oncology Und Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship, Universitätsklinikum Erlangen, Erlangen, Germany; 2 Institute of Radiology, Universitätsklinikum Erlangen, Erlangen, Germany; 3 Preclinical Imaging Platform Erlangen (PIPE), Universitätsklinikum Erlangen, Erlangen, Germany; 4 Department of Vascular Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 5 Department of Biomedical Engineering and Physics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 6 Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 7 Bracco Imaging SpA, Centro Ricerche Bracco, Colleretto Giacosa, Turin, Italy &astThese authors contributed equally to this work Correspondence: Iwona Cicha, Universitätsklinikum Erlangen, Glückstr, 10a, Erlangen, 91054, Germany, Tel +49 9131 85 43953, Fax +49 9131 85 34828, Email Purpose: In this study, a detailed characterization of a rabbit model of atherosclerosis was performed to assess the optimal time frame for evaluating plaque vulnerability using superparamagnetic iron oxide nanoparticle (SPION)-enhanced magnetic resonance imaging (MRI). Methods: The progression of atherosclerosis induced by ballooning and a high-cholesterol diet was monitored using angiography, and the resulting plaques were characterized using immunohistochemistry and histology. Morphometric analyses were performed to evaluate plaque size and vulnerability features. The accumulation of SPIONs (novel dextran-coated SPION Dex and ferumoxytol) in atherosclerotic plaques was investigated by histology and MRI and correlated with plaque age and vulnerability. Toxicity of SPION Dex was evaluated in rats. Results: Weak positive correlations were detected between plaque age and intima thickness, and total macrophage load. A strong negative correlation was observed between the minimum fibrous cap thickness and plaque age as well as the mean macrophage load. The accumulation of SPION in the atherosclerotic plaques was detected by MRI 24 h after administration and was subsequently confirmed by Prussian blue staining of histological specimens. Positive correlations between Prussian blue signal in atherosclerotic plaques, plaque age, and macrophage load were detected. Very little iron was observed in the histological sections of the heart and kidney, whereas strong staining of SPION Dex and ferumoxytol was detected in the spleen and liver. In contrast to ferumoxytol, SPION Dex administration in rabbits was well tolerated without inducing hypersensitivity. The maximum tolerated dose in rat model was higher than 100 mg Fe/kg. Conclusion: Older atherosclerotic plaques with vulnerable features in rabbits are a useful tool for investigating iron oxide-based contrast agents for MRI. Based on the experimental data, SPION Dex particles constitute a promising candidate for further clinical translation as a safe formulation that offers the possibility of repeated administration free from the risks associated with other types of magnetic contrast agents. Keywords: atherosclerosis, plaque vulnerability, rabbit model, macrophages, histology, tissue iron, SPION-enhanced MRI Despite steady developments in anatomical and functional imaging techniques, > 50% of culprit atherosclerotic plaques are still identified in the acute clinical setting when they manifest as myocardial infarction, sudden death or stroke. 1 As decision making in patients with atherosclerotic cardiovascular disease (CVD) currently relies on the measurement of stenosis degree, new approaches must be developed to reliably assess plaque rupture risk and thus reduce the risk of life-threatening cardiovascular events. Early detection of plaques prone to instability using existing imaging modalities in clinical settings could greatly facilitate targeted therapy to inhibit disease progression and prevent acute ischemic events. Magnetic resonance imaging (MRI), a non-ionizing modality characterized by good spatial resolution and soft tissue contrast, 2 is considered a suitable technique for detecting -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology